Are you a healthcare professional?

This website contains promotional information for Chiesi's respiratory products, and is intended solely for UK healthcare professionals. Please confirm below, or go back to the home page.

UK-RES-2101606 August 2021

You are now leaving Chiesi's website

By clicking this link, you will be taken to a website that is not owned or controlled by Chiesi. Chiesi is not responsible for the content provided on that site.

Go back

UK-RES-2101574 August 2021


Think triple (ICS/LABA/LAMA),
think Trimbow®

The only extrafine formulation ICS/LABA/LAMA combination1-3

Designed to reach the large and small airways1,2,4

Trimbow pMDI 87/5/9 is licensed for use as maintenance treatment in both adult asthma and moderate to severe COPD1 and Trimbow NEXThaler 88/5/9 is licensed for use as maintenance treatment in moderate to severe COPD only2

Trimbow® Device

See full licenses below

Adult Asthma

Trimbow 87/5/9 is indicated for maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting β2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.1


Trimbow pMDI 87/5/9 and NEXThaler 88/5/9 are indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1 of the SPC).1,2
For additional information to share with your patients who have been prescribed Trimbow, please visit our Trimbow patient and carer site.

To request a visit from a Chiesi representative to learn more about Trimbow, please click here.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.